Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GX-BP1
- Development stage
- Preclinical
- Lead developer
- Genexine
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous, Inhalation
01
Overview
GX-BP1 is a biological proteolysis-targeting chimera (bioPROTAC) developed by Genexine for the treatment of lung squamous cell carcinoma and other solid tumors. It specifically targets the SOX2 protein, a transcription factor traditionally considered "undruggable" that is highly expressed in squamous cell lung cancer. GX-BP1 works by inducing the cellular degradation of SOX2 via the proteasomal pathway, thereby inhibiting oncogenic activity and tumor growth. The candidate has demonstrated high target selectivity and significant tumor growth inhibition in preclinical lung cancer mouse models and is currently undergoing preclinical toxicity studies. The development is supported by a joint research project with Takeda Pharmaceuticals.
- Other names
- SOX2 bioPROTACSOX-2 bioPROTACSOX 2 bioPROTAC
02
Targets
SOX2 (SRY-box transcription factor 2)
Beyond the preview
Go deeper on GX-BP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GX-BP1.